academic article

• Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. 2017
• PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS..  Journal of medical genetics.  53:800-811. 2016
• TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer..  Nucleic acids research.  43:6945-6958. 2015
• Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer..  Cancer research.  74:3084-3091. 2014
• Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status..  Scientific reports.  4:-. 2014
• Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer..  BMC medical genomics.  7:-. 2014
• APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma..  Cancer research.  73:7222-7231. 2013
• Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel..  Human molecular genetics.  22:3038-3047. 2013
• Assessment of hepatocyte growth factor in ovarian cancer mortality..  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.  20:1638-1648. 2011
• Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity..  The Journal of clinical investigation.  116:1994-2004. 2006